

NCI Alliance for Nanotechnology in Cancer

In 2005, the National Cancer Institute (NCI) of the National Institutes of Health (NIH) established the NCI Alliance for Nanotechnology in Cancer program to accelerate integration of nanotechnology into cancer research and oncology.


Output and Impact

The NCI Alliance for Nanotechnology in Cancer has opened doors to new nanotechnology enabled diagnostic and therapeutic tools for cancer.


The alliance has enabled:

- 7% increase in funding applications relative to all NCI R01 applications
- 4,000+ publications
- 3.5x more citations than research produced by non-Alliance grants
- 200+ patents
- 125 startup companies
- 34 clinical trials

Convergence



Translation



“For every \$1 invested by NCI over a 15 year period, the Centers of Cancer Nanotechnology Excellence leveraged approximately \$8 in federal, academic, and commercial equity”

Nano.gov
U.S. National Nanotechnology Initiative

For more information visit
www.cancer.gov/nano/research/alliance

The NCI Alliance for Nanotechnology in Cancer is one example of a program that is part of the National Nanotechnology Initiative (NNI). The NNI is a U.S. Government research and development (R&D) initiative involving 20 departments and independent agencies working together toward the shared vision of "a future in which the ability to understand and control matter at the nanoscale leads to a revolution in technology and industry that benefits society." For more information visit nano.gov.

Source: Hartshorn, C.M; Russell, L.M.; Grodzinski, P. (2019) National Cancer Institute Alliance for nanotechnology in cancer—Catalyzing research and translation toward novel cancer diagnostics and therapeutics. WIREs Nanomed Nanobiotechnol. DOI: 10.1002/wnan.1570